These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 32767667)

  • 1. Reply to Deleterious effect of ifosfamide in leiomyosarcoma: Convergence of weak signals.
    D'Ambrosio L; Litière S; Stacchiotti S; Gronchi A
    Cancer; 2020 Oct; 126(20):4615-4616. PubMed ID: 32767667
    [No Abstract]   [Full Text] [Related]  

  • 2. Deleterious effect of ifosfamide in leiomyosarcoma: Convergence of weak signals.
    Penel N; Ryckewaert T; Pannier D
    Cancer; 2020 Oct; 126(20):4614-4615. PubMed ID: 32767671
    [No Abstract]   [Full Text] [Related]  

  • 3. Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
    D'Ambrosio L; Touati N; Blay JY; Grignani G; Flippot R; Czarnecka AM; Piperno-Neumann S; Martin-Broto J; Sanfilippo R; Katz D; Duffaud F; Vincenzi B; Stark DP; Mazzeo F; Tuchscherer A; Chevreau C; Sherriff J; Estival A; Litière S; Sents W; Ray-Coquard I; Tolomeo F; Le Cesne A; Rutkowski P; Stacchiotti S; Kasper B; Gelderblom H; Gronchi A;
    Cancer; 2020 Jun; 126(11):2637-2647. PubMed ID: 32129883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mesna, doxorubicin, ifosfamide and dacarbazine chemotherapy for uterine leiomyosarcoma: a report of two cases.
    Minobe S; Todo Y; Suzuki Y; Aoyagi Y; Umazume T; Okamoto K; Kato H
    J Obstet Gynaecol Res; 2011 Jun; 37(6):645-9. PubMed ID: 21375676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interstitial pneumonitis associated with ifosfamide therapy.
    Baker WJ; Fistel SJ; Jones RV; Weiss RB
    Cancer; 1990 May; 65(10):2217-21. PubMed ID: 2112039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
    Santoro A; Tursz T; Mouridsen H; Verweij J; Steward W; Somers R; Buesa J; Casali P; Spooner D; Rankin E
    J Clin Oncol; 1995 Jul; 13(7):1537-45. PubMed ID: 7602342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy of soft tissue sarcoma--a clinical evaluation of treatment over ten years.
    Wall N; Starkhammar H
    Acta Oncol; 2003; 42(1):55-61. PubMed ID: 12665332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination chemotherapy with doxorubicin, dacarbazine, and ifosfamide in advanced adult soft tissue sarcoma. Canadian Sarcoma Group--National Cancer Institute of Canada Clinical Trials Group.
    Bramwell V; Quirt I; Warr D; Verma S; Young V; Knowling M; Eisenhauer E
    J Natl Cancer Inst; 1989 Oct; 81(19):1496-9. PubMed ID: 2778839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ifosfamide with and without adriamycin in advanced uterine leiomyosarcoma.
    Hawkins RE; Wiltshaw E; Mansi JL
    Cancer Chemother Pharmacol; 1990; 26 Suppl():S26-9. PubMed ID: 2347045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose tamoxifen modulates drug resistance to doxorubicin, dacarbazine and ifosfamide in metastatic uterine leiomyosarcoma.
    Yeh KH; Lu YS; Hsiao CH; Cheng AL
    Anticancer Res; 2003; 23(6D):5133-7. PubMed ID: 14986591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained response of sarcomatoid renal-cell carcinoma to MAID chemotherapy: case report and review of the literature.
    Bangalore N; Bhargava P; Hawkins MJ; Bhargava P
    Ann Oncol; 2001 Feb; 12(2):271-4. PubMed ID: 11300337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meta-analysis of ifosfamide-based combination chemotherapy in advanced soft tissue sarcoma.
    Verma S; Younus J; Stys-Norman D; Haynes AE; Blackstein M;
    Cancer Treat Rev; 2008 Jun; 34(4):339-47. PubMed ID: 18313854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in the chemotherapy of soft tissue sarcomas.
    Benjamin RS; Baker LH; O'Bryan RM; Moon TE; Gottlieb JA
    Med Clin North Am; 1977 Sep; 61(5):1039-43. PubMed ID: 895246
    [No Abstract]   [Full Text] [Related]  

  • 14. Multimodal treatment with doxorubicin, cisplatin, and ifosfamide for the treatment of advanced or metastatic uterine leiomyosarcoma: a unicentric experience.
    Hadoux J; Rey A; Duvillard P; Lhommé C; Balleyguier C; Haie-Meder C; Morice P; Tazi Y; Leary A; Larue C; Pautier P
    Int J Gynecol Cancer; 2015 Feb; 25(2):296-302. PubMed ID: 25581897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group.
    Le Cesne A; Judson I; Crowther D; Rodenhuis S; Keizer HJ; Van Hoesel Q; Blay JY; Frisch J; Van Glabbeke M; Hermans C; Van Oosterom A; Tursz T; Verweij J
    J Clin Oncol; 2000 Jul; 18(14):2676-84. PubMed ID: 10894866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ifosfamide and etoposide in the treatment of advanced soft tissue sarcomas.
    Blair SC; Zalupski MM; Baker LH
    Am J Clin Oncol; 1994 Dec; 17(6):480-4. PubMed ID: 7977164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ifosfamide plus doxorubicin in metastatic adult sarcomas: a multi-institutional phase II trial.
    Loehrer PJ; Sledge GW; Nicaise C; Usakewicz J; Hainsworth JD; Martelo OJ; Omura G; Braun TJ
    J Clin Oncol; 1989 Nov; 7(11):1655-9. PubMed ID: 2681554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment results obtained in metastatic soft-tissue sarcoma with a combination of doxorubicin and dacarbazine or doxorubicin and ifosfamide.
    Weh HJ; Agarwal K; Zornig C; Schwarz R; Dietel M; Hossfeld DK
    Cancer Chemother Pharmacol; 1993; 31 Suppl 2():S189-93. PubMed ID: 8453696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Olaratumab Approved for Soft-Tissue Sarcoma.
    Cancer Discov; 2016 Dec; 6(12):1297. PubMed ID: 27827816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG).
    Sleijfer S; Ouali M; van Glabbeke M; Krarup-Hansen A; Rodenhuis S; Le Cesne A; Hogendoorn PC; Verweij J; Blay JY
    Eur J Cancer; 2010 Jan; 46(1):72-83. PubMed ID: 19853437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.